

**General**

**Common Present on Admission Diagnosis**

|                          |  |         |
|--------------------------|--|---------|
| <input type="checkbox"/> | Acidosis   | Post-op |
| <input type="checkbox"/> | Acute Post-Hemorrhagic Anemia  | Post-op |
| <input type="checkbox"/> | Acute Renal Failure  | Post-op |
| <input type="checkbox"/> | Acute Respiratory Failure  | Post-op |
| <input type="checkbox"/> | Acute Thromboembolism of Deep Veins of Lower Extremities   | Post-op |
| <input type="checkbox"/> | Anemia   | Post-op |
| <input type="checkbox"/> | Bacteremia   | Post-op |
| <input type="checkbox"/> | Bipolar disorder, unspecified  | Post-op |
| <input type="checkbox"/> | Cardiac Arrest   | Post-op |
| <input type="checkbox"/> | Cardiac Dysrhythmia  | Post-op |
| <input type="checkbox"/> | Cardiogenic Shock  | Post-op |
| <input type="checkbox"/> | Decubitus Ulcer  | Post-op |
| <input type="checkbox"/> | Dementia in Conditions Classified Elsewhere  | Post-op |
| <input type="checkbox"/> | Disorder of Liver  | Post-op |
| <input type="checkbox"/> | Electrolyte and Fluid Disorder   | Post-op |
| <input type="checkbox"/> | Intestinal Infection due to Clostridium Difficile  | Post-op |
| <input type="checkbox"/> | Methicillin Resistant Staphylococcus Aureus Infection  | Post-op |
| <input type="checkbox"/> | Obstructive Chronic Bronchitis with Exacerbation   | Post-op |
| <input type="checkbox"/> | Other Alteration of Consciousness  | Post-op |
| <input type="checkbox"/> | Other and Unspecified Coagulation Defects  | Post-op |
| <input type="checkbox"/> | Other Pulmonary Embolism and Infarction  | Post-op |
| <input type="checkbox"/> | Phlebitis and Thrombophlebitis   | Post-op |
| <input type="checkbox"/> | Protein-calorie Malnutrition   | Post-op |
| <input type="checkbox"/> | Psychosis, unspecified psychosis type  | Post-op |
| <input type="checkbox"/> | Schizophrenia Disorder   | Post-op |
| <input type="checkbox"/> | Sepsis   | Post-op |
| <input type="checkbox"/> | Septic Shock   | Post-op |
| <input type="checkbox"/> | Septicemia   | Post-op |
| <input type="checkbox"/> | Type II or Unspecified Type Diabetes Mellitus with Mention of Complication, Not Stated as Uncontrolled | Post-op |
| <input type="checkbox"/> | Urinary Tract Infection, Site Not Specified  | Post-op |

**Elective Outpatient, Observation, or Admission (Single Response)**

|                       |   |  |
|-----------------------|---|--|
| <input type="radio"/> | Elective outpatient procedure: Discharge following routine recovery | Routine, Continuous, PACU & Post-op  |
| <input type="radio"/> | Outpatient observation services under general supervision           | Diagnosis:<br>Admitting Physician:<br>Patient Condition:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="radio"/> | Outpatient in a bed - extended recovery                             | Diagnosis:<br>Admitting Physician:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="radio"/> | Admit to Inpatient  | Diagnosis:<br>Admitting Physician:<br>Level of Care:<br>Patient Condition:<br>Bed request comments:<br>Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.<br>PACU & Post-op |

**Admission or Observation (Single Response)**

Patient has active outpatient status order on file

|  |  |
|--|--|
| <input type="checkbox"/> Admit to Inpatient  | Diagnosis:<br>Admitting Physician:<br>Level of Care:<br>Patient Condition:<br>Bed request comments:<br>Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.<br>PACU & Post-op |
| <input type="checkbox"/> Outpatient observation services under general supervision | Diagnosis:<br>Admitting Physician:<br>Patient Condition:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="checkbox"/> Outpatient in a bed - extended recovery                   | Diagnosis:<br>Admitting Physician:<br>Bed request comments:<br>PACU & Post-op  |
| <input type="checkbox"/> Transfer patient  | Level of Care:<br>Bed request comments:<br>Scheduling/ADT  |
| <input type="checkbox"/> Return to previous bed                                    | Routine, Until discontinued, Starting S, Scheduling/ADT  |

**Admission (Single Response)**

Patient has active status order on file

|   |  |
|---|--|
| <input type="checkbox"/> Admit to inpatient     | Diagnosis:<br>Admitting Physician:<br>Level of Care:<br>Patient Condition:<br>Bed request comments:<br>Certification: I certify that based on my best clinical judgment and the patient's condition as documented in the HP and progress notes, I expect that the patient will need hospital services for two or more midnights.<br>PACU & Post-op |
| <input type="checkbox"/> Transfer patient       | Level of Care:<br>Bed request comments:<br>Scheduling/ADT  |
| <input type="checkbox"/> Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT  |

**Transfer (Single Response)**

Patient has active inpatient status order on file

|   |   |
|---|---|
| <input type="checkbox"/> Transfer patient       | Level of Care:<br>Bed request comments:<br>Scheduling/ADT |
| <input type="checkbox"/> Return to previous bed | Routine, Until discontinued, Starting S, Scheduling/ADT   |

**Code Status**

|   |  |
|---|--|
| <input type="checkbox"/> Full Code                | Code Status decision reached by:<br>Post-op            |
| <input type="checkbox"/> DNR (Do Not Resuscitate) |  |
| <input type="checkbox"/> DNR (Do Not Resuscitate) | Does patient have decision-making capacity?<br>Post-op |

|   |  |
|---|--|
| <input type="checkbox"/> Consult to Palliative Care Service | Priority:<br>Reason for Consult?<br>Order?<br>Name of referring provider:<br>Enter call back number: |
| <input type="checkbox"/> Consult to Social Work             | Reason for Consult:<br>Post-op   |
| <input type="checkbox"/> Modified Code                      | Does patient have decision-making capacity?<br>Modified Code restrictions:<br>Post-op                |
| <input type="checkbox"/> Treatment Restrictions             | Treatment Restriction decision reached by:<br>Specify Treatment Restrictions:<br>Post-op             |

### Isolation

|  |         |
|--|---------|
| <input type="checkbox"/> Airborne isolation status | Details |
| <input type="checkbox"/> Contact isolation status  | Details |
| <input type="checkbox"/> Droplet isolation status  | Details |
| <input type="checkbox"/> Enteric isolation status  | Details |

### Precautions

|   |  |
|---|--|
| <input type="checkbox"/> Aspiration precautions | Post-op  |
| <input type="checkbox"/> Fall precautions       | Increased observation level needed:<br>Post-op |
| <input type="checkbox"/> Latex precautions      | Post-op  |
| <input type="checkbox"/> Seizure precautions    | Increased observation level needed:<br>Post-op |

## Nursing

### Vital Signs

|   |                                     |
|---|-------------------------------------|
| <input type="checkbox"/> Vital signs - T/P/R/BP | Routine, Per unit protocol, Post-op |
| <input type="checkbox"/> Vital signs - T/P/R/BP | Routine, Every 4 hours, Post-op     |
| <input type="checkbox"/> Vital signs - T/P/R/BP | Routine, Every 8 hours, Post-op     |

### Activity

|  |   |
|--|---|
| <input type="checkbox"/> Ambulate with assistance      | Routine, 3 times daily<br>Specify: with assistance<br>Post-op                                   |
| <input type="checkbox"/> Must be up for meals          | Routine, Until discontinued, Starting S, Post-op  |
| <input type="checkbox"/> Bed rest with bedside commode | Routine, Until discontinued, Starting S<br>Bathroom Privileges: with bedside commode<br>Post-op |

### Nursing

|  |   |
|--|---|
| <input type="checkbox"/> Neurological assessment   | Routine, Every 8 hours<br>Assessment to Perform:<br>Post-op                   |
| <input type="checkbox"/> Assess operative site     | Routine, Every 8 hours<br>For bleeding, Post-op                               |
| <input type="checkbox"/> Cardiac output monitoring | Routine, Every 15 min<br>Record:<br>Post-op                                   |
| <input type="checkbox"/> Daily weights             | Routine, Daily, Post-op   |
| <input type="checkbox"/> Oral care                 | Routine, Every 8 hours<br>While awake, Post-op                                |
| <input type="checkbox"/> Strict intake and output  | Routine, Every hour, Post-op  |
| <input type="checkbox"/> Head of bed 30 degrees    | Routine, Until discontinued, Starting S<br>Head of bed: 30 degrees<br>Post-op |

|  |   |
|--|---|
| <input type="checkbox"/> Heating pad   | Routine, As needed<br>To shoulder as needed for pain, Post-op   |
| <input type="checkbox"/> Lung pillow to bedside                                      | Routine, Until discontinued, Starting S<br>Please instruct patient how to use the pillow to stabilize the chest and abdomen while coughing, Post-op   |
| <input type="checkbox"/> Foley catheter care   | Routine, Until discontinued, Starting S<br>Orders: Maintain, to gravity<br>Post-op  |
| <input type="checkbox"/> Foley catheter - discontinue                                | Routine, Once, Post-op  |
| <input type="checkbox"/> Chest tube to water seal                                    | Routine, Until discontinued, Starting S, Post-op  |
| <input type="checkbox"/> Chest tube to continuous suction                            | Routine, Until discontinued, Starting S<br>Level of suction: 20 cm H2O<br>Post-op   |
| <input type="checkbox"/> Wound care instructions (free text)                         | Routine, Daily<br>Change chest tube dressing. Also tape tube to flank for security. DO NOT use petroleum jelly gauze around the chest tube exit site.   |
| <input type="checkbox"/> Setup for chest tube removal                                | Routine, Once For 1 Occurrences<br>Please bring to bedside: 1 biohazard bag, 1 suture removal kit, 1 16 gauge needle, 1 4 X 4 gauze, 1 petroleum jelly gauze, 1 blue chuck, 1 silk tape 2 inch, Post-op |
| <input type="checkbox"/> Patient education for incentive spirometry                  | Routine, Once<br>Patient/Family:<br>Education for:<br>For incentive spirometry, Post-op   |
| <input type="checkbox"/> Patient education for Acapella (Green flutter valve)        | Routine, Once<br>Patient/Family:<br>Education for:<br>For Acapella (Green flutter valve), Post-op   |
| <input type="checkbox"/> Patient education for deep-breathing and coughing exercises | Routine, Once<br>Patient/Family:<br>Education for:<br>For deep-breathing and coughing exercises, Post-op  |
| <input type="checkbox"/> Tobacco cessation education                                 | Routine, Once, Post-op  |

### Notify

|   |   |
|---|---|
| <input type="checkbox"/> Notify Physician for vitals:   | Routine, Until discontinued, Starting S<br>Temperature greater than: 100.3<br>Temperature less than:<br>Systolic BP greater than: 180<br>Systolic BP less than: 90<br>Diastolic BP greater than: 110<br>Diastolic BP less than:<br>MAP less than:<br>Heart rate greater than (BPM): 100<br>Heart rate less than (BPM): 50<br>Respiratory rate greater than: 40<br>Respiratory rate less than: 14<br>SpO2 less than: |
| <input type="checkbox"/> Notify Physician for urine output  | Routine, Until discontinued, Starting S, Less than 200 milliliters per shift, Post-op   |
| <input type="checkbox"/> Notify Physician PRIOR to starting any cardiac drips                       | Routine, Once For 1 Occurrences, Post-op  |
| <input type="checkbox"/> Notify Physician PRIOR to transfusing blood or blood products              | Routine, Once For 1 Occurrences, Post-op  |
| <input type="checkbox"/> Notify Physician PRIOR to colloid or crystalloid bolus greater than 250 mL | Routine, Once For 1 Occurrences, Post-op  |

### Diet

|                              |   |
|------------------------------|---|
| <input type="checkbox"/> NPO | Diet effective now, Starting S<br>NPO:<br>Pre-Operative fasting options:<br>Post-op |
|------------------------------|---|

|  |  |
|--|--|
| <input type="checkbox"/> Diet - Clear advance to regular           | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: Regular<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Post-op                         |
| <input type="checkbox"/> Diet - Clear advance to Hearth Healthy    | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: Heart Healthy<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Post-op                   |
| <input type="checkbox"/> Diet - Clear advance to 1800 Carb Control | Diet effective now, Starting S<br>Diet(s): Clear Liquids<br>Advance Diet as Tolerated? Yes<br>Target Diet: 1800 Carb control diabetic diet<br>Advance target diet criteria:<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Post-op |
| <input type="checkbox"/> Diet - Full liquids                       | Diet effective now, Starting S<br>Diet(s): Full Liquids<br>Advance Diet as Tolerated?<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Post-op   |
| <input type="checkbox"/> Diet - Regular                            | Diet effective now, Starting S<br>Diet(s): Regular<br>Advance Diet as Tolerated?<br>Liquid Consistency:<br>Fluid Restriction:<br>Foods to Avoid:<br>Post-op  |

## IV Fluids

### IV Fluids (Single Response)

|  |  |
|--|--|
| <input type="checkbox"/> sodium chloride 0.9 % infusion  | 75 mL/hr, intravenous, continuous, Post-op |
| <input type="checkbox"/> lactated Ringer's infusion  | 75 mL/hr, intravenous, continuous, Post-op |
| <input type="checkbox"/> dextrose 5 % and sodium chloride 0.45 % with potassium chloride 20 mEq/L infusion | 75 mL/hr, intravenous, continuous, Post-op |
| <input type="checkbox"/> sodium chloride 0.45 % infusion   | 75 mL/hr, intravenous, continuous, Post-op |
| <input type="checkbox"/> sodium chloride 0.45 % 1,000 mL with sodium bicarbonate 75 mEq/L infusion         | 75 mL/hr, intravenous, continuous, Post-op |
| <input type="checkbox"/> Custom IV Fluid   | intravenous, continuous, Post-op           |

## Medications

### PostOp Antibiotics

|   |   |
|---|---|
| <input type="checkbox"/> ceFAZolin (ANCEF) IV - For Patients LESS than or EQUAL to 120 kg | <input type="checkbox"/> ceFAZolin (ANCEF) IV<br>2 g, intravenous, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis |
|---|---|

|   |  |
|---|--|
| <input type="checkbox"/> ceFAZolin (ANCEF) IV - For Patients GREATER than 120 kg        |  |
| <input type="checkbox"/> ceFAZolin (ANCEF) IV   | 3 g, intravenous, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis   |
| <input type="checkbox"/> ampicillin-sulbactam (UNASYN) IV                               | 3 g, intravenous, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis  |
| <input type="checkbox"/> vancomycin (VANCOCIN) IV - for patient with penicillin allergy | 15 mg/kg, intravenous, once, For 1 Doses, Post-op<br>Approximately 12 hours after surgery<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis<br>Indication: Increased MRSA rate (operation specific) |
| <input type="checkbox"/> clindamycin (CLEOCIN) IV - for patient with penicillin allergy | 900 mg, intravenous, for 30 Minutes, once, For 1 Doses, Post-op<br>Type of Therapy: New Anti-Infective Order<br>Reason for Therapy: Surgical Prophylaxis   |

### Cardiac Drips

|   |  |
|---|--|
| <input type="checkbox"/> phenylephrine (NEO-SYNEPHRINE) 10 mg/mL in sodium chloride 0.9 % 250 mL infusion | 5-150 mcg/min, intravenous, continuous, Post-op  |
| <input type="checkbox"/> sodium nitroprusside (NIPRIDE) in dextrose 5% 250 mL infusion                    | 0.3-8 mcg/kg/min, intravenous, continuous, Post-op<br>START AT 2 MICROGRAMS/KILOGRAM/MINUTE (SUGGESTED RANGE 0.5-8). TITRATE TO MAINTAIN SBP LESS THAN 170 UP TO 7 MICROGRAMS/KILOGRAM/MINUTE. NOTIFY MD IF GREATER THAN 7 MICROGRAMS/KILOGRAM/MINUTE IS REQUIRED. |
| <input type="checkbox"/> niCARDipine (CARDENE) IV infusion  | 2.5-15 mg/hr, intravenous, continuous, Post-op<br>START AT 5 MILLIGRAM/HOUR. TITRATE TO KEEP SBP LESS THAN 170 (SUGGESTED RANGE 5-15 MILLIGRAM/HOUR). NOTIFY MD IF GREATER THAN 15 MILIGRAM/HOUR IS REQUIRED. MAY CAUSE Q-T INTERVAL PROLONGATION                  |
| <input type="checkbox"/> nitroglycerin infusion   | 2-200 mcg/min, intravenous, continuous, Post-op<br>START AT 2 MICROGRAMS/MIN. TITRATE FOR A MAP OF 60-70 (SUGGESTIVE RANGE LESS THAN OR EQUAL TO 10 MICROGRAMS/MIN)  |
| <input type="checkbox"/> DOPamine (INTROPIN) infusion   | 2-20 mcg/kg/min, intravenous, continuous, Post-op<br>START AT 5MICROGRAMS/KILOGRAM/MINUTE. TITRATE FOR TO MAINTAIN MAP GREATER THAN 60 OR CI GREATER THAN 2.2 (SUGGESTED RANGE 2-10 MICROGRAM/KILOGRAM/MIN)  |
| <input type="checkbox"/> DOBUTamine (DOBUTREX) infusion   | 0.5-20 mcg/kg/min, intravenous, continuous, Post-op<br>START AT 5MICROGRAMS/KILOGRAM/MINUTE. TITRATE FOR TO MAINTAIN MAP GREATER THAN 60 OR CI GREATER THAN 2.2 (SUGGESTED RANGE 2-10 MICROGRAM/KILOGRAM/MIN)  |
| <input type="checkbox"/> epINEPHrine (ADRENALIN) in sodium chloride 0.9 % 250 mL infusion                 | 2-50 mcg/min, intravenous, continuous, Post-op<br>TITRATE TO MAINTAIN MAP GREATER THAN 60 OR CI GREATER THAN 2.2 (SUGGESTED RANGE 0.03-0.15 MICROGRAM/KILOGRAM/MINUTE)   |
| <input type="checkbox"/> milrinone (PRIMACOR) in dextrose 5% infusion                                     | 0.125-0.75 mcg/kg/min, intravenous, continuous, Post-op<br>MAINTAIN SBP GREATER THAN 90 (SUGGESTED RANGE 0.125-0.75 MICROGRAMS/KILOGRAMS PER MINUTE)   |
| <input type="checkbox"/> vasopressin (PITRESSIN) 0.4 Units/mL in sodium chloride 0.9 % 100 mL infusion    | 0.04 Units/min, intravenous, continuous, Post-op   |
| <input type="checkbox"/> norEPInephrine (LEVOPHED) infusion   | 4-50 mcg/min, intravenous, continuous, Post-op   |

### amIODarone (CORDArone) 24-hour Infusions (Hard STOP) (Single Response)

|   |                                   |
|---|-----------------------------------|
| <input type="checkbox"/> CENTRAL Line: amIODarone (CORDArone) 150 mg BOLUS followed by 24-hour Infusion for Atrial Fibrillation | <b>"Followed by" Linked Panel</b> |
|---|-----------------------------------|

|   |   |
|---|---|
| [ ] amIODarone (CORDArone) 150 mg BOLUS   | 150 mg, intravenous, once, Starting S, For 1 Doses<br>Patients should be monitored for QTc prolongation. Use 0.2 Micron Filter Tubing for administration.   |
| [ ] amIODarone (CORDArone) 900 mg/ 250 mL NS  | 1 mg/min, intravenous, continuous, Starting H+10 Minutes, For 6 Hours   |
| [ ] REDUCE rate for amIODarone (CORDArone) 900 mg/ 250 mL infusion  | 0.5 mg/min, intravenous, continuous, Starting H+6 Hours, For 18 Hours<br>Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infuson for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a CENTRAL line or PICC line. Do not take down 1st infusion until entire content of bag is infused.   |
| ( ) PERIPHERAL Line: amIODarone (CORDArone) 150 mg BOLUS followed by 24-hour Infusion for Atrial Fibrillation | <b>"Followed by" Linked Panel</b>   |
| [ ] amIODarone (CORDArone) 150 mg BOLUS   | 150 mg, intravenous, once, Starting S, For 1 Doses<br>Patients should be monitored for QTc prolongation.  |
| [ ] amIODarone (CORDArone) 450 mg/ 250 mL infusion  | 1 mg/min, intravenous, continuous, Starting H+10 Minutes, For 6 Hours<br>Start with 1 mg/min for 6 hours. Decrease to 0.5 mg/min for 18 hours. Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infuson for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a central line or PICC line if infusion duration is GREATER THAN 24 hours. |
| [ ] REDUCE rate for amIODarone (CORDArone) 450 mg/ 250 mL infusion  | 0.5 mg/min, intravenous, continuous, Starting H+6 Hours, For 18 Hours<br>Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infuson for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a central line or PICC line if infusion duration is GREATER THAN 24 hours.   |
| ( ) NO BOLUS - Central Line: amIODarone (CORDArone) 24-hour Infusion for Atrial Fibrillation                  | <b>"Followed by" Linked Panel</b>   |
| [ ] amIODarone (CORDArone) 900 mg/ 250 mL NS  | 1 mg/min, intravenous, continuous, For 6 Hours<br>Start with 1 mg/min for 6 hours. Decrease to 0.5 mg/min for 18 hours. Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infuson for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a CENTRAL line or PICC line. Use 0.2 Micron Filter Tubing for administration.                     |
| [ ] REDUCE rate for amIODarone (CORDArone) 900 mg/ 250 mL NS  | 0.5 mg/min, intravenous, continuous, Starting H+6 Hours, For 18 Hours<br>Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infuson for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a CENTRAL line or PICC line. Do not take down 1st infusion until entire content of bag is infused.   |
| ( ) NO BOLUS - Peripheral Line: amIODarone (CORDArone) 24-hour Infusion for Atrial Fibrillation               | <b>"Followed by" Linked Panel</b>   |
| [ ] amIODarone (CORDArone) 450 mg/ 250 mL infusion - 1st bag  | 1 mg/min, intravenous, continuous, Starting H, For 6 Hours<br>Start with 1 mg/min for 6 hours. Decrease to 0.5 mg/min for 18 hours. Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infuson for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a central line or PICC line if infusion duration is GREATER THAN 24 hours.            |

|  |   |
|--|---|
| <input type="checkbox"/> REDUCE rate for amlODarone (CORDArone) 450 mg/250 mL infusion | 0.5 mg/min, intravenous, once, Starting H+6 Hours, For 1 Doses<br>Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infusion for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a central line or PICC line if infusion duration is GREATER THAN 24 hours. Do not take down 1st infusion until entire content of bag is infused. |
| <input type="checkbox"/> amlODarone (CORDArone) infusion solution -2nd bag             | 0.5 mg/min, intravenous, continuous, Starting H+8 Hours, For 16 Hours<br>Patients should be monitored for QTc prolongation. Use in-line filter to help prevent Phlebitis. HOLD Infusion for heart rate LESS THAN 60 or pauses GREATER THAN 2.5 seconds. MUST be infused via a central line or PICC line if infusion duration is GREATER THAN 24 hours.  |

**amlODarone (PACErone) tablet**

You MUST be sure the oral tablet order is set to start TOMORROW with the start time set to 24 hours AFTER the start time of the INITIAL infusion order above.

|  |   |
|--|---|
| <input type="checkbox"/> amlODarone (PACERONE) tablet **** You MUST CHANGE the START DATE to TOMORROW and set the Start TIME to be 24 hours after the Start Time of the Infusion | oral, every 24 hours, Starting H+24 Hours<br>amiodarone (Pacerone) tablets must start 24 hours after the start of the infusion order. |
|--|---|

**Medications**

|   |   |
|---|---|
| <input type="checkbox"/> docusate sodium (COLACE) capsule                                 | 100 mg, oral, 2 times daily, Post-op  |
| <input type="checkbox"/> calcium carbonate oyster shell (OS-CAL) tablet                   | 500 mg, oral, 4 times daily, Post-op  |
| <input type="checkbox"/> alum-mag hydroxide-simeth (MAALOX) 200-200-20 mg/5 mL suspension | 30 mL, oral, every 4 hours PRN, indigestion, Post-op  |
| <input type="checkbox"/> sucralfate (CARAFATE) 100 mg/mL suspension                       | 1 g, oral, every 6 hours scheduled, Post-op   |
| <input type="checkbox"/> digOXIN (LANOXIN) injection                                      | intravenous, Post-op  |
| <input type="checkbox"/> digOXIN (LANOXIN) tablet   | oral, Post-op<br>Monitor HR, rhythm and BP. Monitor serum potassium, magnesium, calcium, and serum creatinine.  |
| <input type="checkbox"/> metoprolol (LOPRESSOR) 5 mg/5 mL injection                       | 5 mg, intravenous, Post-op<br>Hold for systolic blood pressure LESS than 110 and heart rate LESS than 60<br>HOLD parameters for this order:<br>Contact Physician if:  |
| <input type="checkbox"/> metoprolol tartrate (LOPRESSOR) tablet                           | 25 mg, oral, 2 times daily at 0600, 1800, Post-op<br>HOLD parameters for this order: Hold Parameters requested<br>HOLD for: 110 mmHg<br>HOLD for Heart Rate LESS than: Other<br>Please specify: 60<br>Contact Physician if: |

**Mild Pain (1-3)**

|  |   |
|--|---|
| <input type="checkbox"/> Acetaminophen Oral or Nasogastric or Rectal | <b>"Or" Linked Panel</b><br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources)  |
| <input type="checkbox"/> acetaminophen (TYLENOL) tablet              | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3), fever, Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources)  |
| <input type="checkbox"/> acetaminophen (TYLENOL)suspension           | 650 mg, oral, every 6 hours PRN, mild pain (score 1-3), fever, Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Use if patient cannot swallow tablet. |



|  |   |
|--|---|
| <input type="checkbox"/> acetaminophen (TYLENOL) suppository | 650 mg, rectal, every 6 hours PRN, mild pain (score 1-3), fever, Post-op<br>Maximum of 3 grams of acetaminophen per day from all sources. (Cirrhosis patients maximum: 2 grams per day from all sources). Use if patient cannot swallow tablet. |
|--|---|

#### Moderate Pain (4-6) (Single Response)

|  |   |
|--|---|
| <input type="checkbox"/> acetaminophen-codeine (TYLENOL #3) 300-30 mg per tablet | 1 tablet, oral, every 4 hours PRN, moderate pain (score 4-6), Post-op |
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO) 5-325 mg per tablet   | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op |
| <input type="checkbox"/> oxyCODone-acetaminophen (PERCOCET) 5-325 mg per tablet  | 1 tablet, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op |
| <input type="checkbox"/> traMADol (ULTRAM) tablet                                | 50 mg, oral, every 6 hours PRN, moderate pain (score 4-6), Post-op    |

#### Severe Pain (7-10) (Single Response)

|  |   |
|--|---|
| <input type="checkbox"/> HYDROcodone-acetaminophen (NORCO 10-325) 10-325 mg per tablet | 1 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op      |
| <input type="checkbox"/> oxyCODone-acetaminophen (PERCOCET) 10-325 mg per tablet       | 1 tablet, oral, every 6 hours PRN, severe pain (score 7-10), Post-op      |
| <input type="checkbox"/> morPHINE injection  | 4 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op   |
| <input type="checkbox"/> fentaNYL (SUBLIMAZE) injection                                | 50 mcg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op |
| <input type="checkbox"/> hydromorPHONE (DILAUDID) injection                            | 0.8 mg, intravenous, every 3 hours PRN, severe pain (score 7-10), Post-op |

#### Antiemetics

|   |  |
|---|--|
| <input checked="" type="checkbox"/> ondansetron (ZOFTRAN) IV or Oral                    | <b>"Or" Linked Panel</b>   |
| <input checked="" type="checkbox"/> ondansetron ODT (ZOFTRAN-ODT) disintegrating tablet | 4 mg, oral, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is able to tolerate oral medication.   |
| <input checked="" type="checkbox"/> ondansetron (ZOFTRAN) 4 mg/2 mL injection           | 4 mg, intravenous, every 8 hours PRN, nausea, vomiting, Post-op<br>Give if patient is UNable to tolerate oral medication OR if a faster onset of action is required.   |
| <input checked="" type="checkbox"/> promethazine (PHENERGAN) IV or Oral or Rectal       | <b>"Or" Linked Panel</b>   |
| <input checked="" type="checkbox"/> promethazine (PHENERGAN) 12.5 mg IV                 | 12.5 mg, intravenous, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral or rectal medication OR if a faster onset of action is required. |
| <input checked="" type="checkbox"/> promethazine (PHENERGAN) tablet                     | 12.5 mg, oral, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is able to tolerate oral medication.   |
| <input checked="" type="checkbox"/> promethazine (PHENERGAN) suppository                | 12.5 mg, rectal, every 6 hours PRN, nausea, vomiting, Post-op<br>Give if ondansetron (ZOFTRAN) is ineffective and patient is UNable to tolerate oral medication.   |

#### Itching (Single Response)

|   |   |
|---|---|
| <input type="checkbox"/> Itching - For Patients LESS than 70 years old    |   |
| <input type="checkbox"/> diphenhydrAMINE (BENADRYL) injection             | 12.5 mg, intravenous, every 4 hours PRN, itching, Post-op |
| <input type="checkbox"/> Itching - For Patients 70-76 Years Old           |   |
| <input type="checkbox"/> cetirizine (ZyrTEC) tablet                       | 10 mg, oral, daily PRN, itching, Post-op                  |
| <input type="checkbox"/> Itching - For Patients GREATER than 77 Years Old |   |
| <input type="checkbox"/> cetirizine (ZyrTEC) tablet                       | 5 mg, oral, daily PRN, itching, Post-op                   |

#### Insomnia: For Patients LESS than 70 years old (Single Response)

|   |   |
|---|---|
| <input type="checkbox"/> zolpidem (AMBIEN) tablet | 5 mg, oral, nightly PRN, sleep, Post-op |
|---|---|

ramelteon (ROZEREM) tablet 8 mg, oral, nightly PRN, sleep, Post-op

**Insomnia: For patients GREATER than or EQUAL to 70 years old (Single Response)**

ramelteon (ROZEREM) tablet 8 mg, oral, nightly PRN, sleep, Post-op

**VTE**

**DVT Risk and Prophylaxis Tool (Single Response)**

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Low Risk of DVT

Low Risk (Single Response)

Low risk of VTE

Routine, Once

Low risk: Due to low risk, no VTE prophylaxis is needed.

Will encourage early ambulation

PACU & Post-op

Moderate Risk of DVT - Surgical

Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated.

Moderate Risk

Moderate risk of VTE

Routine, Once, PACU & Post-op

Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)

Patient is currently receiving therapeutic anticoagulation

Routine, Once

No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.

Therapy for the following:

PACU & Post-op

Contraindications exist for pharmacologic prophylaxis

Routine, Once

No pharmacologic VTE prophylaxis due to the following contraindication(s):

PACU & Post-op

enoxaparin (LOVENOX) injection (Single Response)

enoxaparin (LOVENOX) syringe

40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1

enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min

30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1

For Patients with CrCL LESS than 30 mL/min

enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min

30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1

For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min

|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                                | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)               | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk of DVT - Non-Surgical   |  |
| Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated. |  |
| <input type="checkbox"/> Moderate Risk   |  |
| <input type="checkbox"/> Moderate risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                               | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |

|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)                             | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk of DVT - Surgical<br>Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. |  |
| <input type="checkbox"/> High Risk   |  |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |

|  |   |
|--|---|
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op  |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)                                 | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:  |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:   |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |   |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op   |
| <input type="checkbox"/> High Risk of DVT - Non-Surgical<br>Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. |   |
| <input type="checkbox"/> High Risk   |   |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op   |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)  |   |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op  |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCl LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCl LESS than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min   |

|   |  |
|---|--|
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection   | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection  | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)  | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet   | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)   | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)   |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis   | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous  | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings  | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous  | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk of DVT - Surgical (Hip/Knee)<br>Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis. |  |
| <input type="checkbox"/> High Risk  |  |
| <input type="checkbox"/> High risk of VTE   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation   | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis  | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> apixaban (ELIQUIS) tablet  | 2.5 mg, oral, every 12 hours, Starting S+1, PACU & Post-op<br>Indications:   |
| <input type="checkbox"/> aspirin chewable tablet  | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> aspirin (ECOTRIN) enteric coated tablet  | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)   |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - hip arthroplasty  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - knee arthroplasty   | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty  | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min.  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.  |

|  |  |
|--|--|
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission                               | 10 mg, oral, daily at 0600 (time critical), Starting S+1, PACU & Post-op<br>To be Given on Post Op Day 1.<br>Indications:  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |

#### DVT Risk and Prophylaxis Tool (Single Response)

Low Risk Definition Moderate Risk Definition

Pharmacologic prophylaxis must be addressed. Mechanical prophylaxis is optional unless pharmacologic is contraindicated. High Risk Definition

Both pharmacologic AND mechanical prophylaxis must be addressed.

Age less than 60 years and NO other VTE risk factors One or more of the following medical conditions: One or more of the following medical conditions:

Patient already adequately anticoagulated CHF, MI, lung disease, pneumonia, active inflammation, dehydration, varicose veins, cancer, sepsis, obesity, previous stroke, rheumatologic disease, sickle cell disease, leg swelling, ulcers, venous stasis and nephrotic syndrome Thrombophilia (Factor V Leiden, prothrombin variant mutations, anticardiolipin antibody syndrome; antithrombin, protein C or protein S deficiency; hyperhomocysteinemia; myeloproliferative disorders)

Age 60 and above Severe fracture of hip, pelvis or leg

Central line Acute spinal cord injury with paresis

History of DVT or family history of VTE Multiple major traumas

Anticipated length of stay GREATER than 48 hours Abdominal or pelvic surgery for CANCER

Less than fully and independently ambulatory Acute ischemic stroke

Estrogen therapy History of PE

Moderate or major surgery (not for cancer)

Major surgery within 3 months of admission

Low Risk of DVT

|  |  |
|--|--|
| <input type="checkbox"/> Low Risk (Single Response)  |  |
| <input type="checkbox"/> Low risk of VTE   | Routine, Once<br>Low risk: Due to low risk, no VTE prophylaxis is needed.<br>Will encourage early ambulation<br>PACU & Post-op   |
| <input type="checkbox"/> Moderate Risk of DVT - Surgical   |  |
| Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated. |  |
| <input type="checkbox"/> Moderate Risk   |  |
| <input type="checkbox"/> Moderate risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                               | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                                | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patient weight of 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)               | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |



|  |  |
|--|--|
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk of DVT - Non-Surgical   |  |
| Address pharmacologic prophylaxis by selecting one of the following. Mechanical prophylaxis is optional unless pharmacologic prophylaxis is contraindicated. |  |
| <input type="checkbox"/> Moderate Risk   |  |
| <input type="checkbox"/> Moderate risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> Moderate Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                               | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                                | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT), do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs)               | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |

|  |   |
|--|---|
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op   |
| <input type="checkbox"/> High Risk of DVT - Surgical   |   |
| Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.                             |   |
| <input type="checkbox"/> High Risk   |   |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op   |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Surgical Patient (Single Response)  |   |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op  |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op  |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:  |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:   |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |   |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>   |

|  |  |
|--|--|
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <b>( ) High Risk of DVT - Non-Surgical</b>   |  |
| Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.                             |  |
| <b>[ ] High Risk</b>   |  |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op  |
| <b>[ ] High Risk Pharmacological Prophylaxis - Non-Surgical Patient (Single Response)</b>  |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <b>( ) enoxaparin (LOVENOX) injection (Single Response)</b>  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe  | 40 mg, subcutaneous, daily at 1700 (time critical), Starting S   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min   | 30 mg, subcutaneous, daily at 1700 (time critical), Starting S<br>For Patients with CrCL LESS than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily, Starting S<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, PACU & Post-op<br>If the patient does not have a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min.<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <b>[ ] Mechanical Prophylaxis (Single Response)</b>  |  |
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis  | Routine, Once<br>No mechanical VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op   |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place sequential compression device and antiembolic stockings   | <b>"And" Linked Panel</b>  |
| <input type="checkbox"/> Place/Maintain sequential compression device continuous   | Routine, Continuous, PACU & Post-op  |
| <input type="checkbox"/> Place antiembolic stockings   | Routine, Once, PACU & Post-op  |
| <b>( ) High Risk of DVT - Surgical (Hip/Knee)</b>  |  |

Address both pharmacologic and mechanical prophylaxis by ordering from Pharmacological and Mechanical Prophylaxis.

|  |  |
|--|--|
| <input type="checkbox"/> High Risk   |  |
| <input type="checkbox"/> High risk of VTE  | Routine, Once, PACU & Post-op  |
| <input type="checkbox"/> High Risk Pharmacological Prophylaxis - Hip or Knee (Arthroplasty) Surgical Patient (Single Response)                 |  |
| <input type="checkbox"/> Patient is currently receiving therapeutic anticoagulation  | Routine, Once<br>No pharmacologic VTE prophylaxis because: patient is already on therapeutic anticoagulation for other indication.<br>Therapy for the following:<br>PACU & Post-op   |
| <input type="checkbox"/> Contraindications exist for pharmacologic prophylaxis   | Routine, Once<br>No pharmacologic VTE prophylaxis due to the following contraindication(s):<br>PACU & Post-op  |
| <input type="checkbox"/> apixaban (ELIQUIS) tablet   | 2.5 mg, oral, every 12 hours, Starting S+1, PACU & Post-op<br>Indications:   |
| <input type="checkbox"/> aspirin chewable tablet   | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> aspirin (ECOTRIN) enteric coated tablet   | 162 mg, oral, daily, Starting S+1, PACU & Post-op  |
| <input type="checkbox"/> enoxaparin (LOVENOX) injection (Single Response)  |  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - hip arthroplasty   | 40 mg, subcutaneous, daily at 0600 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - knee arthroplasty  | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1   |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients with CrCL LESS than 30 mL/min - knee/hip arthroplasty                     | 30 mg, subcutaneous, daily at 0600 (time critical), Starting S+1<br>For Patients with CrCL LESS than 30 mL/min.  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min                 | 30 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight between 100-139 kg and CrCl GREATER than 30 mL/min.  |
| <input type="checkbox"/> enoxaparin (LOVENOX) syringe - For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min                  | 40 mg, subcutaneous, 2 times daily at 0600, 1800 (time critical), Starting S+1<br>For Patients weight 140 kg or GREATER and CrCl GREATER than 30 mL/min  |
| <input type="checkbox"/> fondaparinux (ARIXTRA) injection  | 2.5 mg, subcutaneous, daily, Starting S+1, PACU & Post-op<br>If the patient does not have a history or suspected case of Heparin-Induced Thrombocytopenia (HIT) do NOT order this medication. Contraindicated in patients LESS than 50kg, prior to surgery/invasive procedure, or CrCl LESS than 30 mL/min<br>This patient has a history of or suspected case of Heparin-Induced Thrombocytopenia (HIT): |
| <input type="checkbox"/> heparin (porcine) injection   | 5,000 Units, subcutaneous, every 8 hours, S+1 at 6:00 AM, PACU & Post-op   |
| <input type="checkbox"/> heparin (porcine) injection (Recommended for patients with high risk of bleeding, e.g. weight < 50kg and age > 75yrs) | 5,000 Units, subcutaneous, every 12 hours, S+1 at 6:00 AM, PACU & Post-op<br>Recommended for patients with high risk of bleeding, e.g. weight LESS than 50kg and age GREATER than 75yrs.   |
| <input type="checkbox"/> rivaroxaban (XARELTO) tablet for hip or knee arthroplasty planned during this admission                               | 10 mg, oral, daily at 0600 (time critical), Starting S+1, PACU & Post-op<br>To be Given on Post Op Day 1.<br>Indications:  |
| <input type="checkbox"/> warfarin (COUMADIN) tablet  | oral, daily at 1700 (time critical), Starting S+1, PACU & Post-op<br>Indication:   |
| <input type="checkbox"/> Pharmacy consult to manage warfarin (COUMADIN)  | STAT, Until discontinued, Starting S<br>Indication:  |
| <input type="checkbox"/> Mechanical Prophylaxis (Single Response)  |  |

|   |   |
|---|---|
| <input type="checkbox"/> Contraindications exist for mechanical prophylaxis               | Routine, Once<br>No mechanical VTE prophylaxis due to the following<br>contraindication(s):<br>PACU & Post-op |
| <input type="checkbox"/> Place/Maintain sequential compression device<br>continuous       | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place sequential compression device and antiembolic<br>stockings | <b>"And" Linked Panel</b>   |
| <input type="checkbox"/> Place/Maintain sequential compression device<br>continuous       | Routine, Continuous, PACU & Post-op   |
| <input type="checkbox"/> Place antiembolic stockings                                      | Routine, Once, PACU & Post-op   |

## Labs

### STAT Labs

|   |                              |
|---|------------------------------|
| <input type="checkbox"/> CBC with platelet and differential | STAT For 1 Occurrences, PACU |
| <input type="checkbox"/> Arterial blood gas                 | STAT For 1 Occurrences, PACU |
| <input type="checkbox"/> Basic metabolic panel              | STAT For 1 Occurrences, PACU |
| <input type="checkbox"/> Prothrombin time with INR          | STAT For 1 Occurrences, PACU |
| <input type="checkbox"/> Partial thromboplastin time        | STAT For 1 Occurrences, PACU |
| <input type="checkbox"/> Fibrinogen                         | STAT For 1 Occurrences, PACU |

### Tomorrow

|   |                                    |
|---|------------------------------------|
| <input type="checkbox"/> Basic metabolic panel              | AM draw For 1 Occurrences, Post-op |
| <input type="checkbox"/> CBC with platelet and differential | AM draw For 1 Occurrences, Post-op |
| <input type="checkbox"/> Blood gas, arterial                | AM draw For 1 Occurrences, Post-op |

### X-Ray

|   |   |
|---|---|
| <input type="checkbox"/> Chest 1 Vw                     | Routine, 1 time imaging For 1 , Post-op |
| <input type="checkbox"/> Chest Pa Lateral W Fluoroscopy | Routine, 1 time imaging For 1 , Post-op |
| <input type="checkbox"/> Chest 1 Vw Portable            | Routine, 1 time imaging For 1 , Post-op |

## Cardiology

## Imaging

## Other Studies

### Other Diagnostic Studies

|   |   |
|---|---|
| <input type="checkbox"/> Echocardiogram transesophageal | Routine, 1 time imaging<br>NPO 6 hours prior to exam, Post-op |
|---|---|

## Respiratory

### Respiratory

|   |   |
|---|---|
| <input type="checkbox"/> Oxygen therapy         | Routine, Continuous<br>Device 1:<br>Titrate to keep O2 Sat Above: 92%<br>Indications for O2 therapy:<br>Post-op   |
| <input type="checkbox"/> Ok to extubate         | Routine, Once For 1 Occurrences, Post-op  |
| <input type="checkbox"/> Incentive spirometry   | Routine, Once, Post-op  |
| <input type="checkbox"/> Mechanical ventilation | Routine, Post-op<br>Mechanical Ventilation:<br>Vent Management Strategies:<br>Vent Management Strategies:<br>Vent Management Strategies:<br>Vent Management Strategies: |

## Rehab

## Consults

For Physician Consult orders use sidebar

### Ancillary Consults

|   |   |
|---|---|
| <input type="checkbox"/> Consult to Case Management           | Consult Reason:<br>Post-op  |
| <input type="checkbox"/> Consult to Social Work               | Reason for Consult:<br>Post-op  |
| <input type="checkbox"/> Consult PT eval and treat            | Special Instructions:<br>Weight Bearing Status:   |
| <input type="checkbox"/> Consult PT wound care                | Special Instructions:<br>Location of Wound?<br>Post-op  |
| <input type="checkbox"/> Consult OT eval and treat            | Special Instructions:<br>Weight Bearing Status:   |
| <input type="checkbox"/> Consult to Nutrition Services        | Reason For Consult?<br>Purpose/Topic:<br>Post-op  |
| <input type="checkbox"/> Consult to Spiritual Care            | Reason for consult?<br>Post-op  |
| <input type="checkbox"/> Consult to Speech Language Pathology | Routine, Once<br>Reason for consult:<br>Post-op   |
| <input type="checkbox"/> Consult to Wound Ostomy Care nurse   | Reason for consult:<br>Reason for consult:<br>Reason for consult:<br>Reason for consult:<br>Consult for NPWT:<br>Reason for consult:<br>Post-op |
| <input type="checkbox"/> Consult to Respiratory Therapy       | Reason for Consult?<br>Post-op  |

## Additional Orders